Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD

20.88  -0.07 (-0.33%)

After market: 20.88 0 (0%)

Fundamental Rating

6

ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ACAD could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
ACAD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ACAD reported negative operating cash flow in multiple years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

With an excellent Return On Assets value of 20.23%, ACAD belongs to the best of the industry, outperforming 97.49% of the companies in the same industry.
With an excellent Return On Equity value of 29.93%, ACAD belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
The Return On Invested Capital of ACAD (9.30%) is better than 94.79% of its industry peers.
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROIC 9.3%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

With an excellent Profit Margin value of 22.99%, ACAD belongs to the best of the industry, outperforming 95.69% of the companies in the same industry.
ACAD has a Operating Margin of 8.84%. This is amongst the best in the industry. ACAD outperforms 93.72% of its industry peers.
With an excellent Gross Margin value of 92.08%, ACAD belongs to the best of the industry, outperforming 93.18% of the companies in the same industry.
ACAD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ACAD has an Altman-Z score of 4.75. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.75, ACAD is in the better half of the industry, outperforming 77.02% of the companies in the same industry.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.75
ROIC/WACC0.96
WACC9.68%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ACAD has a Current Ratio of 2.87. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a Current ratio of 2.87. This is in the lower half of the industry: ACAD underperforms 66.25% of its industry peers.
A Quick Ratio of 2.80 indicates that ACAD has no problem at all paying its short term obligations.
With a Quick ratio value of 2.80, ACAD is not doing good in the industry: 64.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.8
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

7

3. Growth

3.1 Past

ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 5000.00%, which is quite impressive.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 22.39%.
The Revenue has been growing by 23.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%

3.2 Future

ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.65% yearly.
The Revenue is expected to grow by 10.99% on average over the next years. This is quite good.
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 42.61, ACAD can be considered very expensive at the moment.
ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 92.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (27.29), we can say ACAD is valued expensively.
A Price/Forward Earnings ratio of 23.65 indicates a rather expensive valuation of ACAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.56% of the companies listed in the same industry.
ACAD is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 42.61
Fwd PE 23.65
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaply inside the industry as 92.28% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaply inside the industry as 91.92% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 70.62
EV/EBITDA 35.45
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
ACAD's earnings are expected to grow with 45.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.45
PEG (5Y)N/A
EPS Next 2Y35.61%
EPS Next 3Y45.23%

0

5. Dividend

5.1 Amount

ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (7/7/2025, 8:00:00 PM)

After market: 20.88 0 (0%)

20.88

-0.07 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners104.58%
Inst Owner Change0%
Ins Owners0.31%
Ins Owner Change3.85%
Market Cap3.49B
Analysts76.15
Price Target27.54 (31.9%)
Short Float %9.31%
Short Ratio6.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.13%
Min EPS beat(2)-109.07%
Max EPS beat(2)-3.19%
EPS beat(4)2
Avg EPS beat(4)-15.12%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)7
Avg EPS beat(12)13.32%
EPS beat(16)10
Avg EPS beat(16)17.13%
Revenue beat(2)1
Avg Revenue beat(2)-4.13%
Min Revenue beat(2)-8.33%
Max Revenue beat(2)0.08%
Revenue beat(4)2
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.66%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.72%
Revenue beat(16)7
Avg Revenue beat(16)-1.86%
PT rev (1m)11.52%
PT rev (3m)8.69%
EPS NQ rev (1m)-2.3%
EPS NQ rev (3m)-18.19%
EPS NY rev (1m)-5.17%
EPS NY rev (3m)-14.8%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE 42.61
Fwd PE 23.65
P/S 3.51
P/FCF 70.62
P/OCF 23.45
P/B 4.57
P/tB 5.39
EV/EBITDA 35.45
EPS(TTM)0.49
EY2.35%
EPS(NY)0.88
Fwd EY4.23%
FCF(TTM)0.3
FCFY1.42%
OCF(TTM)0.89
OCFY4.26%
SpS5.95
BVpS4.57
TBVpS3.87
PEG (NY)2.45
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.23%
ROE 29.93%
ROCE 10.62%
ROIC 9.3%
ROICexc 9.3%
ROICexgc 10.83%
OM 8.84%
PM (TTM) 22.99%
GM 92.08%
FCFM 4.97%
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 151.14%
Profit Quality 21.61%
Current Ratio 2.87
Quick Ratio 2.8
Altman-Z 4.75
F-Score5
WACC9.68%
ROIC/WACC0.96
Cap/Depr(3y)241.2%
Cap/Depr(5y)203.04%
Cap/Sales(3y)1.85%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y17.36%
EPS Next 2Y35.61%
EPS Next 3Y45.23%
EPS Next 5Y44.65%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%18.7%
Revenue Next Year9.35%
Revenue Next 2Y9.97%
Revenue Next 3Y10.61%
Revenue Next 5Y10.99%
EBIT growth 1Y1912.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.12%
EBIT Next 3Y44.84%
EBIT Next 5Y49.94%
FCF growth 1Y188.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y367.79%
OCF growth 3YN/A
OCF growth 5YN/A